OncoPep
North Andover
About OncoPep
OncoPep, Inc. was founded in 2010 to commercialize a novel approach to developing targeted immunotherapeutics against cancer. The company's proprietary core technology was developed in the laboratory of Dr. Kenneth Anderson, M.D., a world leader in cancer treatment, at the Dana Farber Cancer Institute. The technology, which OncoPep has exclusively licensed from Dana Farber, employs a unique combination of proprietary peptides to form a therapeutic cancer vaccine. Vaccines developed from this technology are designed to stimulate the patient’s immune system to attack his or her cancer through an optimized combination of disease-specific peptides and adjuvants (substances that stimulate the immune system).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $28.4M
- Funding stage: Late Stage Venture
- Last round: Series D (Dec 2021)
- Website: oncopep.com
- Phone: +1 978 837 1129
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Canonical: https://fsome.com/organization/oncopep-61449 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.